Antiverse

Executive Summary

Antiverse is a UK-based biotechnology company founded in 2018 that leverages machine learning to design antibodies for challenging therapeutic targets. The company's AI-driven platform aims to streamline and accelerate the traditionally slow and expensive antibody discovery process, addressing unmet patient needs. Currently operating at a pre-clinical stage, Antiverse has not disclosed any funding rounds or valuation, indicating a relatively early stage of development. The company's focus on difficult targets positions it as a potential player in the AI-driven drug discovery space, but the lack of disclosed milestones or partnerships suggests significant uncertainty. With a lean operation based in Cardiff, the company may be poised for growth pending successful fundraising or collaboration announcements.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Round60% success
• Q1 2027Lead Antibody Candidate Nomination40% success
• H1 2027Research Collaboration with Pharma50% success